論文業績 2016-2020
2020
- Kanda Y, Kimura SI, Iino M, Fukuda T, Sakaida E, Oyake T, Yamaguchi H, Fujiwara SI, Jo Y, Okamoto A, Fujita H, Takamatsu Y, Saburi Y, Matsumura I, Yamanouchi J, Shiratori S, Gotoh M, Nakamura S, Tamura K; Japan Febrile Neutropenia Study Group. D-Index-Guided Early Antifungal Therapy Versus Empiric Antifungal Therapy for Persistent Febrile Neutropenia: A Randomized Controlled Noninferiority Trial. J Clin Oncol. 2020 Mar 10;38(8):815-822. doi: 10.1200/JCO.19.01916. Epub 2020 Jan 24. PMID: 31977270.
- Tachibana T, Kanda J, Ishizaki T, Najima Y, Tanaka M, Doki N, Fujiwara SI, Kimura SI, Onizuka M, Takahashi S, Saito T, Mori T, Fujisawa S, Sakaida E, Matsumoto K, Aotsuka N, Gotoh M, Watanabe R, Shono K, Usuki K, Tsukada N, Kanamori H, Kanda Y, Okamoto S; Kanto Study Group for Cell Therapy (KSGCT). Outcomes and Prognostic Factors for Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia Who Underwent Allogeneic Hematopoietic Cell Transplantation: A KSGCT Multicenter Analysis. Biol Blood Marrow Transplant. 2020 May;26(5):998-1004. doi: 10.1016/j.bbmt.2020.01.007. Epub 2020 Jan 18. PMID: 31962165.
- Ohwada C, Sakaida E, Igarashi A, Kobayashi T, Doki N, Mori T, Kato J, Koda Y, Kanamori H, Tanaka M, Tachibana T, Fujisawa S, Nakajima Y, Numata A, Toyosaki M, Aoyama Y, Onizuka M, Hagihara M, Koyama S, Kanda Y, Nakasone H, Shimizu H, Kato S, Watanabe R, Shono K, Sakai R, Saito T, Nakaseko C, Okamoto S. A Prospective, Longitudinal Observation of the Incidence, Treatment, and Survival of Late Acute and Chronic Graft-versus-Host Disease by National Institutes of Health Criteria in a Japanese Cohort. Biol Blood Marrow Transplant. 2020 Jan;26(1):162-170. doi: 10.1016/j.bbmt.2019.09.016. Epub 2019 Sep 16. PMID: 31536824.
- Yonese I, Sakashita C, Imadome K, Kobayashi T, Yamamoto M, Sawada A, Ito Y, Fukuhara N, Hirose A, Takeda Y, Makita M, Endo T, Kimura S, Ishimura M, Miura O, Ohga S, Kimura H, Fujiwara S, Arai A. Nationwide survey of systemic chronic active EBV infection in Japan in accordance with the new WHO classification Blood Advances. (2020) 4 (13): 2918–2926.
- Takaishi K, Takeuchi M, Tsukamoto S, Takayama N, Oshima M, Kimura K, Isshiki Y, Kayamori K, Hino Y, Oshima-Hasegawa N, Mitsukawa S, Takeda Y, Mimura N, Ohwada C, Iseki T, Nakamura S, Eto K, Iwama A, Yokote K, Nakaseko C, Sakaida E. Suppressive effects of anagrelide on cell cycle progression and the maturation of megakaryocyte progenitor cell lines in human induced pluripotent stem cells. Haematologica. 2020 May;105(5):e216-e220. doi: 10.3324/haematol.2018.214841. Epub 2019 Sep 5. PMID: 31488559; PMCID: PMC7193491.
- Nagai Y, Tsukamoto S, Hino Y, Isshiki Y, Yamazaki M, Izumi S, Mishina T, Oshima-Hasegawa N, Mitsukawa S, Takeda Y, Mimura N, Ohwada C, Takeuchi M, Iseki T, Nakaseko C, Sakaida E. Remarkable donor-derived T cell lymphocytosis before engraftment of a bone marrow transplant for acute lymphoblastic leukemia. Leuk Lymphoma. 2020 Jan;61(1):221-224. doi: 10.1080/10428194.2019.1660973. Epub 2019 Sep 5. PMID: 31486335.
- Tachibana T, Ishizaki T, Takahashi S, Najima Y, Kimura SI, Sakaida E, Onizuka M, Mori T, Fujisawa S, Fujiwara SI, Saito T, Hagihara M, Aotsuka N, Gotoh M, Usuki K, Tsukada N, Kanda J, Kanamori H, Kanda Y, Okamoto S; Kanto Study Group for Cell Therapy (KSGCT). Allogeneic hematopoietic cell transplantation in patients with untreated acute myeloid leukemia: a KSGCT multicenter retrospective analysis. Bone Marrow Transplant. 2020 Jul;55(7):1497-1501. doi: 10.1038/s41409-019-0689-8. Epub 2019 Sep 19. PMID: 31537900.
- Kurosawa S, Mori A, Tsukagoshi M, Onishi Y, Ohwada C, Mori T, Goto H, Asano-Mori Y, Nawa Y, Hino M, Fukuchi T, Mori Y, Yamahana R, Inamoto Y, Fukuda T. Current Status and Needs of Long-Term Follow-Up Clinics for Hematopoietic Cell Transplantation Survivors: Results of a Nationwide Survey in Japan. Biol Blood Marrow Transplant. 2020;26(5):949-55.
- Kubo K, Hori M, Ohta K, Handa H, Hatake K, Matsumoto M, Hagiwara S, Ohashi K, Nakaseko C, Suzuki K, Ito S, Kinoshita G, Shelat S. G, Miyoshi M, Takezako N. Elotuzumab plus lenalidomide and dexamethasone for newly diagnosed multiple myeloma: a randomized, open-label, phase 2 study in Japan. Int J Hematol. 2020;111(1):65-74
- Kimura SI, Kanda Y, Iino M, Fukuda T, Sakaida E, Oyake T, Yamaguchi H, Fujiwara SI, Jo Y, Okamoto A, Fujita H, Takamatsu Y, Saburi Y, Matsumura I, Yamanouchi J, Shiratori S, Gotoh M, Nakamura S, Tamura K; Japan Febrile Neutropenia Study Group. Efficacy and safety of micafungin in empiric and D-index-guided early antifungal therapy for febrile neutropenia; A subgroup analysis of the CEDMIC trial. Int J Infect Dis. 2020 Nov;100:292-297. doi: 10.1016/j.ijid.2020.08.081. Epub 2020 Sep 3. PMID: 32891738.
- Kikuchi T, Mori T, Ohwada C, Onoda M, Shimizu H, Yokoyama, H, Onizuka M, Koda Y, Kato J, Takeda Y, Hino Y, Mishina T, Sakaida E, Shono K, Nagao Y, Yokota A, Matsumoto K, Morita K, Okamoto S.Kanto Study Group for Cell, Therapy. Pharmacokinetics of intravenous busulfan as condition for hematopoietic stem cell transplantation: comparison between combinations with cyclophosphamide and fludarabine. Int J Hematol. 2020.in press
- Kawashima N, Ishikawa Y, Atsuta Y, Sawa M, Ozawa Y, Hayashi M, Kohno A, Tomita A, Maeda T, Sakaida E, Usuki K, Hagihara M, Kanamori H, Matsuoka H, Kobayashi M, Asou N, Ohtake S, Matsumura I, Miyazaki Y, Naoe T, Kiyoi H; Japan Adult Leukemia Study Group (JALSG). Allogeneic hematopoietic stem cell transplantation at the first remission for younger adults with FLT3-internal tandem duplication AML: The JALSG AML209-FLT3-SCT study. Cancer Sci. 2020 Jul;111(7):2472-2481. doi: 10.1111/cas.14448. Epub 2020 May 29. PMID: 32391628; PMCID: PMC7484840.
- Hino Y, Muraosa Y, Oguchi M, Yahiro M, Yarita K, Watanabe A, Sakaida E, Yokote K, Kamei K. Drain outlets in patient rooms as sources for invasive fusariosis: an analysis of patients with haematological disorders. J Hosp Infect. 2020 Apr 28:S0195-6701(20)30204-8. doi: 10.1016/j.jhin.2020.04.029. Epub ahead of print. PMID: 32360338.
- Hino M, Matsumura I, Fujisawa S, Ishizawa K, Ono T, Sakaida E, Sekiguchi N, Tanetsugu Y, Fukuhara K, Ohkura M, Koide Y, Takahashi N. Phase 2 study of bosutinib in Japanese patients with newly diagnosed chronic phase chronic myeloid leukemia. Int J Hematol. 2020 Jul;112(1):24-32. doi: 10.1007/s12185-020-02878-x. Epub 2020 Apr 11. PMID: 32279228.
- Muto T, Walker S, Choi K, Hueneman K, Gul Z, Garcia-Manero G, Ma A, Zheng Y, Starczynowski DT, Adaptive response of MDS cells to the inflammatory milieu contributes to sustained myeloid expansion and a competitive advantage. Nature Immunol. 2020 May;21(5):535-545. PMID: 32313245
- Zhong C, Kayamori K, Koide S, Shinoda D, Oshima M, Nakajima-Takagi Y, Nagai Y, Mimura N, Sakaida E, Yamazaki S, Iwano S, Miyawaki A, Ito R, Tohyama K, Yamaguchi K, Furukawa Y, Lennox W, Sheedy J, Weetall M, Iwama A. Efficacy of the novel tubulin polymerization inhibitor PTC-028 for myelodysplastic syndrome. Cancer Sci. 2020 Dec;111(12):4336-4347. doi: 10.1111/cas.14684. Epub 2020 Nov 2. PMID: 33037737; PMCID: PMC7734154.
- Kako S, Kanda Y, Onizuka M, Aotsuka N, Usuki K, Tachibana T, Kobayashi T, Kato J, Yano S, Shimizu H, Shono K, Tanaka M, Tsukamoto S, Mori T, Yamazaki E, Najima Y, Hangaishi A, Hoshino T, Watanabe R, Matsumoto K, Okamoto S; for Kanto Study Group for Cell Therapy (KSGCT). Allogeneic hematopoietic stem cell transplantation for aplastic anemia with pre-transplant conditioning using fludarabine, reduced-dose cyclophosphamide, and low-dose thymoglobulin: A KSGCT prospective study. Am J Hematol. 2020 Mar;95(3):251-257. doi: 10.1002/ajh.25693. Epub 2019 Dec 19. PMID: 31804748.
和文論文
2020
- 堺田惠美子 日本骨髄腫学会編 多発性骨髄腫ガイドライン p84-87. POEMS診療ガイドライン.
- 柴宮明日香、堺田惠美子 『日本臨牀』 78(3): 401-406. 特集「急性白血病-最新の診断と治療」 急性リンパ性白血病のWHO分類.
- 高石浩司、中世古知昭 『急性白血病診療テキスト エキスパートに聞く』 p26-34. FAB 分類とWHO 分類. 中外医学社.
- 石井改、堺田惠美子 『急性白血病診療テキスト エキスパートに聞く』p35-45. 急性骨髄性白血病の予後分類. 中外医学社.
- 三村尚也、井関 徹、堺田惠美子. 日本アフェレシス学会雑誌 39(1):17-23, 2020. POEMS症候群に対する自家末梢血幹細胞移植.
- 柴宮明日香、三村尚也、堺田惠美子. カレントテラピー 38(6): 619-623. 特集「多発性骨髄腫 -クロストークの腫瘍- 」5. 骨髄腫の治療 -原病に対する治療と各種支持療法- 7) 骨髄腫の支持療法 ―骨障害対策から、軽鎖除去、移植時cryotherapyまで―
- 中尾三四郎、塚本祥吉、堺田惠美子. 月刊「血液内科」 81(3): 331-338. 特集 多発性骨髄腫をめぐる病態解析研究と治療の進展 自家移植後のMRD陰性例に対する維持療法の意義.
- 竹田勇輔、堺田惠美子. 「EBM 血液疾患の治療 2021-2022」p413-418.中外医学社. 金倉譲監修 多発性骨髄腫に対する同種移植の現状.
- 堺田惠美子. 臨床血液 61(2020) 4:411-415.ワークライフバランスとキャリア形成
- 堺田惠美子. 臨床血液 61(2020) 6: 698-710. 女性医師のキャリア形成を考える
- 堺田惠美子 臨床血液 日本血液学会 教育講演特別号 61(9): 1306-1316 未治療移植適応骨髄腫患者の治療戦略.
- 松井慎一郎, 武藤朋也, 堺田惠美子. 同種造血幹細胞移植におけるサイトメガロウイルス感染の予防と治療. 月刊「血液内科」 81(5): 681-687. 特集ウイルス感染と血液疾患
- 武藤朋也. 炎症性微小環境によるMDS細胞の増殖機構. 月刊「血液内科」 81(6): 849-855.
- 大和田千桂子, 堺田 惠美子. 特集 特殊または希少な造血器腫瘍に対する診断・病態と治療 POEMS症候群. 月刊「血液内科」 80(5): 705-711.
- 三村尚也. 月刊「血液内科」 特集・多発性骨髄腫をめぐる病態解析研究と治療の進展第「エピゲノム異常を標的とした新たな骨髄腫治療の可能性」 81巻第3号 p298-303 2020年9月
2019
- Takaishi K, Tsukamoto S, Ohwada C, Takeuchi M, Kawasaki Y, Nagai Y, Mishina T,Yamazaki M, Isshiki Y, Kayamori K, Kimura K, Hino Y, Oshima-Hasegawa N, Mitsukawa S, Takeda Y, Mimura N, Iseki T, Nakaseko C, Sakaida E. Low incidence of thromboembolism in multiple myeloma patients receiving immunomodulatory drugs; a retrospective single-institution analysis. J Thromb Thrombolysis. 2019 Jul;48(1):141-148. doi: 10.1007/s11239-019-01809-w. PMID:30673940
- Nagao Y, Mimura N, Takeda J, Yoshida K, Shiozawa Y, Oshima M, Aoyama K, Saraya A, Koide S, Rizq O, Hasegawa Y, Shiraishi Y, Chiba K, Tanaka H, Nishijima D, Isshiki Y, Kayamori K, Kawajiri-Manako C, Oshima-Hasegawa N, Tsukamoto S, Mitsukawa S, Takeda Y, Ohwada C, Takeuchi M, Iseki T, Misawa S, Miyano S, Ohara O, Yokote K, Sakaida E, Kuwabara S, Sanada M, Iwama A, Ogawa S, Nakaseko C. Genetic and transcriptional landscape of plasma cells in POEMS syndrome. Leukemia. 2019 Jul;33(7):1723-1735. doi: 10.1038/s41375-018-0348-x. Epub 2019 Jan 11.
- Suichi T, Misawa S, Sato Y, Beppu M, Sakaida E, Sekiguchi Y, Shibuya K, Watanabe K, Amino H, Kuwabara S. Proposal of new clinical diagnostic criteria for POEMS syndrome.
J Neurol Neurosurg Psychiatry. 2019 Feb;90(2):133-137. doi: 10.1136/jnnp-2018-318514. Epub 2018 Oct 2. PMID: 30279213
- Kawashima N, Akashi A, Nagata Y, Kihara R, Ishikawa Y, Asou N, Ohtake S, Miyawaki S, Sakura T, Ozawa Y, Usui N, Kanamori H, Ito Y, Imai K, Suehiro Y, Kitamura K, Sakaida E, Takeshita A, Suzushima H, Naoe T, Matsumura I, Miyazaki Y, Ogawa S, Kiyoi H; Japan Adult Leukemia Study Group (JALSG). Clinical significance of ASXL2 and ZBTB7A mutations and C-terminally truncated RUNX1-RUNX1T1 expression in AML patients with t(8;21) enrolled in the JALSG AML201 study. Ann Hematol. 2019 J83-91. doi: 10.1007/s00277-018-3492-5. [Epub 2018 Sep24]PMID:30251205
- Miyamura K, Ohnishi K, Ohtake S, Usui N, Nakaseko C, Fujita H, Fujisawa S, Sakura T, Okumura H, Iriyama N, Emi N, Fujimaki K, Honda S, Miyazaki Y, Naoe T. Randomized Study of Imatinib for Chronic Myeloid Leukemia: Comparing Standard Dose Escalation with Aggressive Escalation. Blood Adv. 2019 Feb 12;3(3):312-319. doi:10.1182/bloodadvances.2018025981.PMID:30705033.
- Miki Yamazaki, Chiaki Nakaseko, Masahiro Takeuchi, Shinichi Ozawa, Yasuhiro Ishizuka, Yasuhito Hatanaka, Nagisa Oshima-Hasegawa, Tomoya Muto, Shokichi Tsukamoto, Shio Mitsukawa, Chikako Ohwada, Yusuke Takeda, Naoya Mimura, Tohru Iseki, Motoharu Fukazawa, Emiko Sakaida. Myeloid/lymphoid neoplasm with PDGFRB rearrangement with t(5;10)(q33;q22) harboring a novel breakpoint of the CCDC6–PDGFRB fusion gene. Internal Medicine. 2019Jul 22. doi: 10.2169/internalmedicine.3220-19. [Epub ahead of print] PMID:31327842
- Kimura K, Tsukamoto S, Takaishi K, Isshiki Y, Kayamori K, Hino Y, Ohshima-Hasegawa N, Mitsukawa S, Takeda Y, Mimura N, Takeuchi M, Ohwada C, Iseki T, Nakaseko C, Sakaida E. T315I mutation with lymphoblasts in a newly diagnosed patient with chronic-phase chronic myeloid leukemia. Leuk Lymphoma. 2019 Jun;60(6):1591-1594. doi: 10.1080/10428194.2018.1548704. Epub 2019 Jan 16. PMID: 31161870
- Kanayama K, Chiba T, Oshima M, Kanzaki H, Koide S, Saraya A, Miyagi S, Mimura N, Kusakabe Y, Saito T, Ogasawara S, Suzuki E, Ooka Y, Maruyama H, Iwama A, Kato N. Genome-Wide Mapping of Bivalent Histone Modifications in Hepatic Stem/Progenitor Cells. Stem Cells Int. 2019 Apr 1;2019:9789240. doi: 10.1155/2019/9789240. eCollection 2019. PMID: 31065285
- Tachibana T, Kanda J, Ishizaki T, Najima Y, Tanaka M, Doki N, Fujiwara SI, Kimura SI, Onizuka M, Takahashi S, Saito T, Mori T, Fujisawa S, Sakaida E, Matsumoto K, Aotsuka N, Goto M, Watanabe R, Shono K, Usuki K, Tsukada N, Kanamori H, Kanda Y, Okamoto S; Kanto Study; Group for Cell Therapy (KSGCT). Prognostic index for patients with relapsed or refractory acute myeloid leukemia who underwent hematopoietic cell transplantation: a KSGCT multicenter analysis. Leukemia. 2019 May 30. doi: 10.1038/s41375-019-0494-9. [Epub ahead of print] PMID: 31147621
- Shimizu R, Takeuchi M, Sakaida E, Ohwada C, Toyosaki M, Machida S, Onizuka M, Shono K, Onoda M, Saito T, Yano S, Tanaka M, Fujisawa S, Mori T, Usuki K, Takahashi S, Kanamori H, Nakaseko C, Okamoto S. Efficacy and safety of oral deferasirox treatment for transfusional iron overload in pure red cell aplasia patients after allogeneic stem cell transplantation. Ann Hematol. 2019 May 22. doi: 10.1007/s00277-019-03717-8. [Epub ahead of print] No abstract available. PMID: 31119366
- Hamanaka S, Nakagawa T, Ota S, Iida M, Ohta Y, Isshiki Y, Kasamatsu S, Ishigami H, Taida T, Okimoto K, Saito K, Maruoka D, Matsumura T, Ohwada C, Takeuchi M, Sakaida E, Arai M, Katsuno T, Nakaseko C, Nakatani Y, Kato N. Immunomodulator-associated Epstein-Barr virus-positive mucocutaneous ulcer in a patient with refractory Crohn's disease. Clin J Gastroenterol. 2019 Mar 22. doi: 10.1007/s12328-019-00952-4. [Epub ahead of print] PMID: 30903514
- Katsumata Y, Terada J, Abe M, Suzuki K, Ishiwata T, Ikari J, Takeda Y, Sakaida E, Tsushima K, Tatsumi K. An Analysis of the Clinical Benefit of 37 Bronchoalveolar Lavage Procedures in Patients with Hematologic Disease and Pulmonary Complications. Intern Med. 2019 Apr 15;58(8):1073-1080. doi: 10.2169/internalmedicine.1606-18. Epub 2018 Dec 18. PMID: 30568132
- Iida S, Shimazaki C, Abe M, Nakaseko C.JSH practical guidelines for hematological malignancies, 2018: III. Myeloma-2. Related disorders of multiple myeloma. Int J Hematol. 2019 Jun;109(6):633-640. doi: 10.1007/s12185-019-02640-y. Epub 2019 Apr 8. No abstract available. PMID: 30963472
- Yakushijin K, Ikezoe T, Ohwada C, Kudo K, Okamura H, Goto H, Yabe H, Yasumoto A, Kuwabara H, Fujii S, Kagawa K, Ogata M, Onishi Y, Kohno A, Watamoto K, Uoshima N, Nakamura D, Ota S, Ueda Y, Oyake T, Koike K, Mizuno I, Iida H, Katayama Y, Ago H, Kato K, Okamura A, Kikuta A, Fukuda T. Clinical effects of recombinant thrombomodulin and defibrotide on sinusoidal obstruction syndrome after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2019 May;54(5):674-680. doi: 10.1038/s41409-018-0304-4. Epub 2018 Aug 20.PMID:30127466
- Kizaki M, Takahashi N, Iriyama N, Okamoto S, Ono T, Usui N, Inokuchi K, Nakaseko C, Kurokawa M, Sumi M, Nakamura F, Kawaguchi T, Suzuki R, Yamamoto K, Ohnishi K, Matsumura I, Naoe T; New TARGET investigators. Efficacy and safety of tyrosine kinase inhibitors for newly diagnosed chronic-phase chronic myeloid leukemia over a 5-year period: results from the Japanese registry obtained by the New TARGET system. Int J Hematol. 2019 Apr;109(4):426-439. doi: 10.1007/s12185-019-02613-1. Epub 2019 Feb 14.PMID: 30762219
- Nakamura A, Ohwada C, Takeuchi M, Takeda Y, Tsukamoto S, Mimura N, Nagisa OH, Sugita Y, Tanaka H, Wakita H, Aotsuka N, Matsue K, Yokote K, Ohara O, Nakaseko C, Sakaida E. Detection of MYD88 L265P mutation by next-generation deep sequencing in peripheral blood mononuclear cells of Waldenström's macroglobulinemia and IgM monoclonal gammopathy of undetermined significance. PLoS One. 2019 Sep 4;14(9):e0221941. doi: 10.1371/journal.pone.0221941. PMID: 31483817
- Isshiki Y, Nakajima-Takagi Y, Oshima M, Aoyama K, Rizk M, Kurosawa S, Saraya A, Kondo T, Sakaida E, Nakaseko C, Yokote K, Koseki H, Iwama A. KDM2B in polycomb repressive complex 1.1 functions as a tumor suppressor in the initiation of T-cell leukemogenesis. Blood Adv. 2019 Sep 10;3(17):2537-2549. doi: 10.1182/bloodadvances.2018028522. PMID: 31471323
- Ohwada C, Sakaida E, Igarashi A, Kobayashi T, Doki N, Mori T, Kato J, Koda Y, Kanamori H, Tanaka M, Tachibana T, Fujisawa S, Nakajima Y, Numata A, Toyosaki M, Aoyama Y, Onizuka M, Hagihara M, Koyama S, Kanda Y, Nakasone H, Shimizu H, Kato S, Watanabe R, Shono K, Sakai R, Saito T, Nakaseko C, Okamoto S. A Prospective, Longitudinal Observation of the Incidence, Treatment, and Survival of Late Acute and Chronic Graft-versus-host disease by National Institutes of Health Criteria in a Japanese cohort. Biol Blood Marrow Transplant. 2019 Sep 16. pii: S1083-8791(19)30627-5. doi: 10.1016/j.bbmt.2019.09.016. PMID: 31536824
- Tatsuzo Mishina, Nagisa Oshima-Hasegawa, Shokichi Tsukamoto, Yurie Nagai, Miki Yamazaki, Arata Ishii, Yutaro Hino, Yusuke Isshiki, Koji Takaishi, Kenji Kimura, Kensuke Kayamori, Shintaro Izumi, Shio Mitsukawa, Yusuke Takeda, Naoya Mimura, Chikako Ohwada, Masahiro Takeuchi, Sonoko Misawa, Tohru Iseki, Satoshi Kuwabara, Chiaki Nakaseko, Emiko Sakaida. Successful autologous stem cell transplantation for POEMS syndrome with an unusually large osteolytic lesion: A case report and literature review. International Journal of Myeloma in press
- Tachibana T, Ishizaki T, Takahashi S, Najima Y, Kimura SI, Sakaida E, Onizuka M, Mori T, Fujisawa S, Fujiwara SI, Saito T, Hagihara M, Aotsuka N, Gotoh M, Usuki K, Tsukada N, Kanda J, Kanamori H, Kanda Y, Okamoto S; Kanto Study Group for Cell Therapy (KSGCT). Allogeneic hematopoietic cell transplantation in patients with untreated acute myeloid leukemia: a KSGCT multicenter retrospective analysis. Bone Marrow Transplant. 2019 Sep 19. doi: 10.1038/s41409-019-0689-8. [Epub ahead of print]
- Shimizu H, Doki N, Kanamori H, Sakura T, Mori T, Machida S, Takahashi S, Ohwada C, Fujisawa S, Yano S, Hagihara M, Kanda Y, Onoda M, Gotoh M, Kako S, Taguchi J, Usuki K, Kawai N, Aotsuka N, Okamoto S; Kanto Study Group for Cell Therapy (KSGCT). Prognostic impact of cytogenetic abnormalities in adult patients with Philadelphia chromosome-negative ALL who underwent an allogeneic transplant. Bone Marrow Transplant. 2019 Dec;54(12):2020-2026. doi: 10.1038/s41409-019-0585-2. Epub 2019 Jun 11.PMID: 31186516
- Kubo K, Hori M, Ohta K, Handa H, Hatake K, Matsumoto M, Hagiwara S, Ohashi K, Nakaseko C, Suzuki K, Ito S, Kinoshita G, Shelat SG, Miyoshi M, Takezako N. Elotuzumab plus lenalidomide and dexamethasone for newly diagnosed multiple myeloma: a randomized, open-label, phase 2 study in Japan. Int J Hematol. 2020 Jan;111(1):65-74. doi: 10.1007/s12185-019-02757-0. Epub 2019 Nov 7. PMID: 31701481
- Masahiro Sakaguchi, Hiroki Yamaguchi, Marika Kuboyama, Yuho Najima, Kensuke Usuki, Toshimitsu Ueki, Iekuni Oh, Shinichiro Mori, Eri Kawata, Nobuhiko Uoshima, Yutaka Kobayashi, Shinichi Kako, Kenji Tajika, Katsuhiro Shono, Kensuke Kayamori, Masao Hagihara, Junya Kanda, Hitoji Uchiyama, Junya Kuroda, Naoyuki Uchida, Yasushi Kubota, Shinya Kimura, Saiko Kurosawa, Kenta Date, Nana Nakajima, Atsushi Marumo, Ikuko Omori, Yusuke Fujiwara, Kazuki Terada, Shunsuke Yui, Satoshi Wakita, Kunihito Arai, Tomoaki Kitano, Kazuhiko Kakihana, Yoshinobu Kanda, Kazuteru Ohashi, Takahiro Fukuda, Koiti Inokuchi. Significance of FLT3‐tyrosine kinase domain mutation as a prognostic factor for acute myeloid leukemia. Int J Hematol. 2019 Nov;110(5):566-574. doi: 10.1007/s12185-019-02720-z.
- Kako S, Kanda Y, Onizuka M, Aotsuka N, Usuki K, Tachibana T, Kobayashi T, Kato J, Yano S, Shimizu H, Shono K, Tanaka M, Tsukamoto S, Mori T, Yamazaki E, Najima Y, Hangaishi A, Hoshino T, Watanabe R, Matsumoto K, Okamoto S; for Kanto Study Group for Cell Therapy (KSGCT). Allogeneic hematopoietic stem cell transplantation for aplastic anemia with pre-transplant conditioning using fludarabine, reduced-dose cyclophosphamide, and low-dose thymoglobulin: A KSGCT prospective study. Am J Hematol. 2019 Dec 5. doi: 10.1002/ajh.25693. [Epub ahead of print] PMID: 31804748
- Rizk M, Rizq O, Oshima M, Nakajima-Takagi Y, Koide S, Saraya A, Isshiki Y, Chiba T, Yamazaki S, Ma A, Jin J, Iwama A, Mimura N. Akt inhibition synergizes with polycomb repressive complex 2 inhibition in the treatment of multiple myeloma. Cancer Sci. 2019 Dec;110(12):3695-3707. doi: 10.1111/cas.14207. Epub 2019 Oct 22. PMID: 31571328
和文論文
2019
- 三村尚也. 骨髄腫モデルマウスによる病態の解明と新規治療の開発. 月刊「血液内科」 特集・多発性骨髄腫の分子病態解明の進歩と新たな治療展開. 第78巻第1号p13-17 2019年1月
- 栢森健介, 堺田惠美子. 腎と透析 2019年 増刊号 全身疾患と腎update 第5章 9. 白血病 テーマ:白血病 血液専門医の視点より in press
- 日野裕太郎, 堺田惠美子. 月刊 血液内科 特集/慢性骨髄性白血病(CML)診療の最近の進歩 チロシンキナーゼ阻害薬による有害事象とその対策 2019 in press
- 三村 尚也、井関 徹. 形質細胞性疾患における脾臓病変. 特集・脾臓研究の進歩と臨床. 月刊「血液内科」 第78巻6号p817-820(2019年6月)
- 立花 美智子, 塚本 祥吉, 三川 紫緒, 竹田 勇輔, 大和田 千桂子, 大島 渚, 武内 正博, 三村 尚也, 井関 徹, 中世古 知昭, 堺田 惠美子. HCTC主導骨髄バンクコーディネートシステムによるコーディネート期間の短縮. 日本造血細胞移植学会雑誌. 2019 年 8 巻 2 号 p. 84-89
- 大島渚、堺田惠美子、横手幸太郎 加齢に伴うクローン性造血とアテローム性動脈硬化型心血管障害リスク 『Cardio-Renal Diabetes』 Vol. 8, No. 3., in press
- 石井改、堺田惠美子. 急性リンパ性白血病(ALL).ALLに対する造血細胞移植. 『白血病マニュアル 改訂第4版』in press
- 三村尚也. プロテアソーム阻害剤による心毒性の発症機構. 月刊「血液内科」79巻5号p635-638(2019年11月)
- 三村尚也、堺田惠美子、中世古知昭. POEMS症候群の形質細胞における遺伝子異常.月刊「腫瘍内科」24巻6号p691-696(2019年12月)
- 山崎美貴、塚本祥吉、中世古知昭. 自家移植後の多発性骨髄腫患者に対するイクサゾミブ維持療法. 月刊「血液内科」 in press
- 中世古知昭 [POEMS syndrome: advances in molecular pathophysiology and treatment]. Rinsho Ketsueki. 2019;60(8):979-987. doi: 10.11406/rinketsu.60.979. Japanese.PMID: 31484899
2018
- Watanabe Y, Shimizu N, Iwakawa M, Yamaguchi T, Ban N, Kawana H, Saiki A, Sakaida E, Nakaseko C, Matsuura Y, Aotsuka N, Bujo H, Tatsuno I. Successful treatment of rapidly progressive life-threatening esophageal submucosal hematoma in a patient with van der Hoeve syndrome. J Clin Med Res. 2018;10(2):154-157. PMID: 29317961
- Harada K, Doki N, Hagino T, Miyawaki S, Ohtake S, Kiyoi H, Miyazaki Y, Fujita H, Usui N, Okumura H, Miyamura K, Nakaseko C, Fujieda A, Nagai T, Yamane T, Sakamaki H, Ohnishi K, Naoe T, Ohno R, Ohashi K. Underweight status at diagnosis is associated with poorer outcomes in adult patients with acute myeloid leukemia: a retrospective study of JALSG AML 201. Ann Hematol. 2018 Jan;97(1):73-81. PMID:29196987
- Kumagai T, Nakaseko C, Nishiwaki K, Yoshida C, Ohashi K, Takezako N, Takano H, Kouzai Y, Murase T, Matsue K, Morita S, Sakamoto J, Wakita H, Sakamaki H, Inokuchi K; Kanto CML and Shimousa Hematology Study Groups. Dasatinib cessation after deep molecular response exceeding 2 years and natural killer cell transition during dasatinib consolidation. Cancer Sci. 2018 Jan;109(1):182-192. PMID:29058817
- Iriyama N, Ohashi K, Hashino S, Kimura S, Nakaseko C, Takano H, Koh K, Uchiyama M, Morita S, Sakamoto J, Sakamaki H, Inokuchi K. The efficacy of reduced-dose dasatinib as a subsequent therapy in patients with chronic myeloid leukemia in the chronic phase: The LD-CML Study of the Kanto CML Study Group. Intern Med. 2018;57(1):17-23. PMID: 29033428
- Togasaki E, Shimizu N, Nagao Y, Kawajiri-Manako C, Shimizu R, Oshima-Hasegawa N, Muto T, Tsukamoto S, Sakai S, Takeda Y, Mimura N, Ohwada C, Takeuchi M, Sakaida E, Iseki T, Yoshitomi H, Ohtsuka M, Miyazaki M, Nakaseko C. Long-term efficacy of partial splenic embolization for the treatment of steroid-resistant chronic immune thrombocytopenia. Ann Hematol. 2018 Apr;97(4):655-662. PMID: 29332223
- Kawajiri-Manako C, Sakaida E, Ohwada C, Miyamoto T, Azuma T, Taguchi J, Mori T, Hasegawa Y, Kondo T, Yujiri T, Yoshimitsu M, Imada K, Kurahashi S, Kahata K, Ichinohe T, Hirokawa M, Atsuta Y, Nakaseko C. The efficacy and long-term outcomes of autologous stem cell transplantation in POEMS syndrome: A nation-wide survey in Japan. Biol Blood Marrow Transplant. 2018 Feb 1. pii: S1083-8791(18)30042-9. PMID: 29409882
- Tachibana T, Kanda J, Machida S, Saito T, Tanaka M, Najima Y, Koyama S, Miyazaki T, Yamamoto E, Takeuchi M, Morita S, Kanda Y, Kanamori H, Okamoto S; Kanto Study Group for Cell Therapy (KSGCT). Deferasirox for the treatment of iron overload after allogeneic hematopoietic cell transplantation: multicenter phase I study (KSGCT1302). Int J Hematol. 2018 May;107(5):578-585. PMID: 29305770
- Takagi S, Tsukamoto S, Park J, Johnson KE, Kawano Y, Moschetta M, Liu CJ, Mishima Y, Kokubun K, Manier S, Salem KZ, Huynh D, Sacco A, Forward J, Roccaro AM, Battinelli EM, Ghobrial IM. Platelets enhance Multiple Myeloma progression via IL-1β upregulation. Clin Cancer Res. 2018 May 15;24(10):2430-2439. PMID: 29440174
- Kuwatsuka Y, Tomizawa D, Kihara R, Nagata Y, Shiba N, Iijima-Yamashita Y, Shimada A, Deguchi T, Miyachi H, Tawa A, Taga T, Kinoshita A, Nakayama H, Kiyokawa N, Saito AM, Koh K, Goto H, Kosaka Y, Asou N, Ohtake S, Miyawaki S, Miyazaki Y, Sakura T, Ozawa Y, Usui N, Kanamori H, Ito Y, Imai K, Suehiro Y, Kobayashi S, Kitamura K, Sakaida E, Ogawa S, Naoe T, Hayashi Y, Horibe K, Manabe A, Mizutani S, Adachi S, Kiyoi H. Prognostic value of genetic mutations in adolescent and young adults with acute myeloid leukemia. Int J Hematol. 2018 Feb;107(2):201-210. PMID: 29027108
- Nakamae H, Fukuda T, Nakaseko C, Kanda Y, Ohmine K, Ono T, Matsumura I, Matsuda A, Aoki M, Ito K, Shibayama H. Nilotinib vs imatinib in Japanese patients with newly diagnosed chronic myeloid leukemia in chronic phase: Japanese subgroup of the randomized ENESTnd trial. Int J Hematol 2018 Mar;107(3):327-336, PMID: 29076005
- Harada Y, Nagata Y, Kihara R, Ishikawa Y, Asou N, Ohtake S, Miyawaki S, Sakura T, Ozawa Y, Usui N, Kanamori H, Ito Y, Imai K, Suehiro Y, Kobayashi S, Kitamura K, Sakaida E, Onizuka M, Takeshita A, Ishida F, Suzushima H, Ishizawa K, Naoe T, Matsumura I, Miyazaki Y, Ogawa S, Kiyoi H; Japan Adult Leukemia Study Group JALSG. Prognostic analysis according to the 2017 ELN risk stratification by genetics in adult acute myeloid leukemia patients treated in the Japan Adult Leukemia Study Group (JALSG) AML201 study. Leuk Res. 2018;66:20-27. PMID: 29360622
- Ohwada C, Sakaida E, Kawajiri-Manako C, Nagao Y, Oshima-Hasegawa N, Togasaki E, Muto T, Tsukamoto S, Mitsukawa S, Takeda Y, Mimura N, Takeuchi M, Shimizu N, Misawa S, Iseki T, Kuwabara S, Nakaseko C. Long-term evaluation of physical improvement and survival of autologous stem cell transplantation in POEMS syndrome. Blood. 2018 May 10;131(19):2173-2176. PMID: 29599110
- Takaishi K, Muto T, Mimura N, Takiguchi J, Nagao Y, Oshima-Hasegawa N, Tsukamoto S, Takeda Y, Mitsukawa S, Takeuchi M, Ohwada C, Ota S, Iseki T, Nakaseko C, Sakaida E. Long-term complete remission following tandem autologous stem cell transplantation and consolidative radiotherapy for refractory mediastinal gray-zone lymphoma. Int J Hematol. 2018 :108(4):452-455 [Epub ahead of print] PMID: 29786758
- Kawano Y, Zavidij O, Park J, Moschetta M, Kokubun K, Mouhieddine TH, Manier S, Mishima Y, Murakami N, Bustoros M, Pistofidis RS, Reidy M, Shen YJ, Rahmat M, Lukyanchykov P, Karreci ES, Tsukamoto S, Shi J, Takagi S, Huynh D, Sacco A, Tai YT, Chesi M, Bergsagel PL, Roccaro AM, Azzi J, Ghobrial IM. Blocking IFNAR1 inhibits multiple myeloma-driven Treg expansion and immunosuppression. J Clin Invest. 2018 Jun 1;128(6):2487-2499. PMID: 2955836
- Tsukamoto S, Løvendorf MB, Park J, Salem KZ, Reagan MR, Manier S, Zavidij O, Rahmat M, Huynh D, Takagi S, Kawano Y, Kokubun K, Thrue CA, Nagano K, Petri A, Roccaro AM, Capelletti M, Baron R, Kauppinen S, Ghobrial IM. Inhibition of microRNA-138 enhances bone formation in multiple myeloma bone marrow niche. Leukemia. 2018 Aug;32(8):1739-1750. Epub 2018 Jun 20. PMID: 29925904
- Kayamori K, Shono K, Onoda M & Yokota A. Efficacy and tolerability of rituximab and reduced-dose cyclophosphamide, doxorubicin, vincristine, and prednisolone therapy for elderly patient with diffuse large B-cell lymphoma. Hematology. 2018 Aug 11:1-8. doi: 10.1080/10245332.2018.1509461. [Epub ahead of print] PMID:30101679
- Shionoya Y, Kasai H, Terada J, Abe M, Takeda Y, Sakaida E, Tanabe N, Tatsumi K. Cytomegalovirus pneumonia with progressive lung volume loss. American Journal of Case Reports. 2018 Nov 23;19:1393-1397. doi 10.12659/AJCR.911708.PMID:30467305
- Kawajiri-Manako C, Mimura N, Fukuyo M, Namba H, Rahmutulla B, Nagao Y, Togasaki E, Shimizu R, Oshima-Hasegawa N, Tsukamoto S, Mitsukawa S, Takeda Y, Ohwada C, Takeuchi M, Iseki T, Misawa S, Yokote K, Tsuiji M, Kuwabara S, Sakaida E, Kaneda A, Nakaseko C. Clonal immunoglobulin λ light-chain gene rearrangements detected by next generation sequencing in POEMS syndrome. Am J Hematol. 2018 Sep;93(9):1161-1168.doi:10 10.1002/ajh.25213. Epub 2018 Aug 31.PMID:30015379
- Tanaka H, Kuwabara C, Kayamori K, Shimizu R, Suzuki Y. Therapy-related Myelodysplastic Syndrome after Autologous Stem Cell Transplantation Using Plerixafor for Mobilized Stem Cells in a Patient with Multiple Myeloma. J Clin Exp Hematop. 2018 Sep 19;58(3):148-151. doi: 10.3960/jslrt.18005. Epub 2018 Aug 8.
- Bouyssou JM, Liu CJ, Bustoros M, Sklavenitis-Pistofidis R, Aljawai Y, Manier S, Yosef A, Sacco A, Kokubun K, Tsukamoto S, Perilla Glen A, Huynh D, Castillo JJ, Treon SP, Leblond V, Hermine O, Roccaro AM, Ghobrial IM, Capelletti M. Profiling of circulating exosomal miRNAs in patients with Waldenström Macroglobulinemia. PLoS One. 2018 Oct 4;13(10):e0204589. PMID: 30286096
- Sakaguchi M, Yamaguchi H, Najima Y, Usuki K, Ueki T, Oh I, Mori S, Kawata E, Uoshima N, Kobayashi Y, Kako S, Tajika K, Gomi S, Shono K, Kayamori K, Hagihara M, Kanda J, Uchiyama H, Kuroda J, Uchida N, Kubota Y, Kimura A, Kurosawa S, Nakajima N, Marumo A, Omori I, Fujiwara Y, Yui S, Wakita S, Arai K, Kitano T, Kakihana K, Kanda Y, Ohashi K, Fukuda T, and Inokuchi K. Prognostic impact of low allelic ratio FLT3-ITD and NPM1 mutation in acute myeloid leukemia. Blood advances. 2018 Oct 23;2(20):2744-2754. doi:10.1182. 2018020305.
- Isshiki Y, Iwama A. Emerging role of non-canonical polycomb repressive complexes in normal and malignant hematopoiesis. Exp Hematol. 2018 Dec;68:10-14 PMID:30554637
- Tara S, Isshiki Y, Nakajima-Takagi Y, Oshima M, Aoyama K, Tanaka T, Shinoda D, Koide S, Saraya A, Miyagi S, Manabe I, Matsui H, Koseki H, Bardwell VJ, Iwama A. Bcor insufficiency promotes initiation and progression of myelodysplastic syndrome. Blood. 2018 Sep 18. pii: blood-2018-01-827964. doi: 10.1182/blood-2018-01-827964. [Epub ahead of print]
- Noguchi S, Nakaseko C, Nishiwaki K, Ogasawara H, Ohishi K, Tokuhira M, Noguchi M, Kimura H, Handa H, Mitani K, Miura M, Wakita H, Takahashi N; STAT study group. Switching to nilotinib is associated with deeper molecular responses in chronic myeloid leukemia chronic phase with major molecular responses to imatinib: STAT1 trial in Japan. Int J Hematol. 2018 Aug;108(2):176-183. PMID: 29713954
- Kanakura Y, Shirasugi Y, Yamaguchi H, Koike M, Chou T, Okamoto S, Achenbach H, Wu J, Nakaseko C. A phase 3b, multicenter, open-label extension study of the long-term safety of anagrelide in Japanese adults with essential thrombocythemia. Int J Hematol. 2018 Nov; 108(5):491-8. PMID: 30121892
- Takahashi N, Nishiwaki K, Nakaseko C, Aotsuka N, Sano K, Ohwada C, Kuroki J, Kimura H, Tokuhira M, Mitani K, Fujikawa K, Iwase O, Ohishi K, Kimura F, Fukuda T, Tanosaki S, Takahashi S, Kameoka Y, Nishikawa H, Wakita H, and the STAT study group. Treatment-free remission after two-year consolidation therapy with nilotinib in patients with chronic myeloid leukemia: STAT2 trial in Japan. Haematologica 2018 Nov; 103(11): 1835-42, PMID: 29976734
- Katsumata Y, Terada J, Abe M, Suzuki K, Ishiwata T, Ikari J, Takeda Y, Sakaida E, Tsukshima K, Tatsumi K. An analysis of the clinical benefit of 37 Bronchoalveolar lavage procedures in patients with hematologic disease and pulmonary complications. Intern Med 2018 Dec 18. doi: 10.2169/internalmedicine.1606-18. [Epub ahead of print]
- Kasamatsu T, Ozaki S, Saitoh T, Konishi Jm Sunami K, Itagaki M, Asaoku H, Cho T, Handa H, Hagiwara S, Wakayama T, Negoro A, Takezako N, Harada N, Kuroda Y, Nakaseko C, Miyake T, Inoue N, Hata H, Shimazaki C, Ohno T, Kuroda J, Murayama T, Kobayashi T, Abe M, Ishida T, Nagura E, Shimizu K. Unsuppresssed serum albumin lvels may jeopardize the cinical relevance of the international staging system to patients with light chain myeloma. Hematol Oncol. 2018 Dec, 36(5):792-800. doi: 10.1002/hon.2559. Epub 2018 Sep 19.PMID:30176173
- Fang J*, Muto T*, Kleppe M, Bolanos LC, Hueneman KM, Walker CS, Sampson L, Wellendorf AM, Chetal K, Choi K, Salomonis N, Choi Y, Zheng Y, Cancelas JA, Levine RL, Starczynowski DT, TRAF6 mediates basal activation of NF-kB necessary for hematopoietic stem cell homeostasis. Cell Rep. 2018 Jan 30;22(5):1250-1262. PMID: 29386112. * co-first author
和文論文
- 中世古知昭 多発性骨髄腫に対するVRd療法:Rd療法との比較と自家移植の意義.特集:造血障害とその類縁疾患―最近展開 血液内科 2018; 76(1): 101-105
- 中世古知昭,堺田惠美子.特集:ヘマトネフロロジー:血液・凝固疾患と腎障害,テーマ:3. 腎沈着症 POEMS症候群 (Crow-Fukase症候群) 腎と透析 2018 in press
- 三村尚也,井関徹. 第3章遺伝子関連検査関連事項. 2-(1) 体細胞遺伝子検査 ②血液疾患 ここが知りたい遺伝子診療はてなBOOK. 中外医学社 2018 page115-117(単行本)
- 和泉真太郎,木村賢司,竹田勇輔,塚本祥吉,山﨑美貴,三科達三,長井友莉恵,高石浩司,永尾侑平,大島渚,三川紫緒,三村尚也,武内正博,大和田千桂子,井関徹,太田聡,中世古知昭,堺田惠美子. 高IgM血症を伴いワルデンシュトレームマクログロブリン血症との鑑別を要したMALTリンパ腫. 臨床血液 2018 in press
- 三科達三, 堺田惠美子. POEMS症候群に対する自家幹細胞移植. 血液内科 2018; 77(5): 688-694
- 三村尚也.骨髄腫におけるエピゲノム異常 (III.基礎研究) 特集 多発性骨髄腫 -基礎・臨床研究の最新動向- 日本臨牀 2018 Vol.76 No.7 p1110-1116
- 栢森健介,大和田千桂子,中世古知昭 V. 多発性骨髄腫と関連疾患 11. POEMS症候群の治療 EBM血液疾患の治療,編集:金倉譲,木崎昌弘,鈴木律郎,神田善伸,中外医学社,東京,2018: 412-416(単行本)
- 中世古知昭,堺田惠美子.腎沈着症 POEMS症候群 (Crow-Fukase症候群) 「特集:ヘマトネフロロジー:血液・凝固疾患と腎障害」,腎と透析 2018; 84(4): 566-71
- 中世古知昭,堺田惠美子. POEMS症候群の病態と治療の進歩 特集 多発性骨髄腫―臨床研究の最新動向― 日本臨牀 2018; 76(7):1249-55
- 中世古知昭,堺田惠美子. 実地医家のためのバイオマーカーの最新知識 No.12 血液疾患のバイオマーカー 日本医師会雑誌 2018; 147(8):1632-3
- 東ヶ崎絵美,中世古知昭. 1. 疾患の歴史,病態,特徴,症状と検査所見.「特集 原発性マクログロブリン血症」 血液フロンティア 2018; 28(8):21-27
- 中世古知昭 リンパ系腫瘍 2章 成熟B細胞性腫瘍 9. 形質細胞腫瘍 5) 単クローン性免疫グロブリン沈着病 ③POEMS症候群.WHO血液腫瘍分類~WHO分類2017をうまく活用するために 改訂版,医薬ジャーナル社,大阪,2018:240-243(単行本)
- 中世古知昭 リンパ系腫瘍 2章 成熟B細胞性腫瘍 9. 形質細胞腫瘍 5) 単クローン性免疫グロブリン沈着病 ④TEMPI症候群 WHO血液腫瘍分類~WHO分類2017をうまく活用するために 改訂版,医薬ジャーナル社,大阪,2018:243-244(単行本)
- 中世古知昭 IX章 白血球系疾患:腫瘍性疾患 28. 多発性骨髄腫の類縁疾患 血液専門医テキスト 改訂第3版 in press(単行本)
- 長井友莉恵,堺田惠美子,中世古知昭 15. POEMS症候群とキャッスルマン病. 特集:新たに追加された指定難病キャッスルマン病を理解する 成人病と生活習慣病 2018 in press
- 中世古知昭 形質細胞腫瘍の診断と治療の進歩 日本検査血液学会雑誌 in press
- 中世古知昭 アミロイドーシス 新臨床内科学第10版 in press
- 中世古知昭 H(重)鎖病 新臨床内科学第10版 in press
- 三川紫緒, 大和田千桂子, 中世古知昭, 井関徹, 堺田惠美子. 非血縁者間同種造血幹細胞移植における手紙交換の実態と送付に関わる影響因子の解析. 内科 in press
- 三川紫緒 輸血2018 血液製剤とその適応 アルブミン・免疫グロブリン製剤 内科
2017
- Muto T, Ohwada C, Takaishi K, Isshiki Y, Nagao Y, Hasegawa N, Kawajiri-Manako C, Togasaki E, Shimizu R, Tsukamoto S, Sakai S, Takeda Y, Mimura N, Takeuchi M, Sakaida E, Misawa S, Shimizu N, Iseki T, Kuwabara S, Nakaseko C. Safety and efficacy of granulocyte-colony stimulating factor monotherapy for peripheral blood stem cell collection in POEMS Syndrome. Biol Blood Marrow Transplant 2017;23(2):361-3, PMID: 27840209
- Konuma T, Kondo T, Yamashita T, Uchida N, Fukuda T, Ozawa Y, Ohashi K, Ogawa H, Kato C, Takahashi S, Kanamori H, Eto T, Nakaseko C, Kohno A, Ichinohe T, Atsuta Y, Takami A, Yano S. Outcome of allogeneic hematopoietic stem cell transplantation in adult patients with acute myeloid leukemia harboring trisomy 8. Ann Hematol 2017; 96(3): 469-78, PMID: 28058493
- Ishizawa K, Fukuhara N, Nakaseko C, Chiba S, Ogura M, Okamoto A, Sunaga Y, Tobinai K. Safety, efficacy and pharmacokinetics of humanized anti-CD52 monoclonal antibody alemtuzumab in Japanese patients with relapsed or refractory B-cell chronic lymphocytic leukemia. Jpn J Clin Oncol 2017;47(1):54-60. PMID: 28122892
- Shimizu R, Ohwada C, Nagao Y, Togasaki E, Kawajiri C, Muto T, Tsukamoto S, Sakai S, Takeda Y, Mimura N, Takeuchi M, Sakaida E, Iseki T, Nakaseko C. The successful treatment of a cord blood transplant recipient with Varicella Zoster virus meningitis, radiculitis and myelitis with foscarnet. Intern Med. 2017;56(3):353-6., PMID: 28154282
- Takahashi K, Suzuki E, Yokoyama M, Inoue M, Wakamatsu T, Saito T, Kusakabe Y, Ogasawara S, Ooka Y, Tawada A, Nagao Y, Nakaseko C, Chiba T. Successful treatment of hepatocellular carcinoma complicated by Fanconi anemia. Case Rep Gastroenterol. 2017;11(1):29-35. PMID: 28203135
- Sakaida E, Ebata T, Iwasawa S, Kurimoto R, Yonemori S, Ota S, Nakatani Y, Sekine I, Takiguchi Y. Potential activity of amrubicin as a salvage therapy for Merkel cell carcinoma - a case report. Int Med 2017;56(5):567-70., PMID: 28250307
- Hasegawa N, Oshima M, Sashida G, Matsui H, Koide S, Saraya A, Wang C, Muto T, Takane K, Kaneda A, Shimoda K, Nakaseko C, Yokote K, Iwama A. Impact of combinatorial dysfunctions in epigenetic regulators Tet2 and Ezh2 on the epigenome in the pathogenesis of myelodysplastic syndrome. Leukemia 2017; 31(4):861-71. PMID: 27694924
- Togasaki E, Takeda J, Yoshida K, Shiozawa Y, Takeuchi M, Oshima M, Saraya A, Iwama A, Yokote K, Sakaida E, Hirase C, Takeshita A, Imai K, Okumura H, Morishita Y, Usui N, Takahashi N, Fujisawa S, Shiraishi Y, K Chiba K, Tanaka H, Kiyoi H, Ohnishi K, Ohtake S, Asou N, Kobayashi Y, Miyazaki Y, Miyano S, Ogawa S, Matsumura I, Nakaseko C, Naoe T for the Japan Adult Leukemia Study Group (JALSG). Frequent somatic mutations in epigenetic regulators in newly-diagnosed chronic myeloid leukemia. Blood Cancer J 2017 7, e559; doi:10.1038/bcj.2017.36
- Shimizu N, Tanaka S, Watanabe Y, Tokuyama W, Hiruta N, Ohwada C, Sakaida E, Nakaseko C, Tatsuno I. Syndrome of Inappropriate Antidiuretic Hormone Secretion in a Patient with Mucosa-associated Lymphoid Tissue Lymphoma. Intern Med. 2017;56(23):3225-3229., PMID: 29021471
- Doki N, Kakihana K, Ashizawa M, Onoda M, Ohwada C, Kobayashi S, Gotoh M, Fujisawa S, Okamoto S, for the Kanto Study Group for Cell Therapy. Clinical characteristics of calcineurin inhibitor-induced pain syndrome (CIPS) after allogeneic hematopoietic stem cell transplantation. J Hematopoietic Cell Transplant 2017; 6(2): 115-119
- Naoya Mimura.Novel therapeutic approaches to achieve the cure of multiple myeloma. Chiba Medical J. 2017; 93E:17-23.
- Isshiki Y, Ohwada C, Sakaida E, Onoda M, Aotsuka N, Tanaka H, Fukazawa M, Cho R, Sugawara T, Kawaguchi T, Hara S, Yokota A. CD20 positivity and white blood cell count predict treatment outcomes in Philadelphia chromosome-negative acute lymphoblastic leukemia patients ineligible for pediatric-inspired chemotherapy. Jpn J Clin Oncol. 2017;47(11):1047-1054.PMID:28973362
- Nakamae H, Fukuda T, Nakaseko C, Kanda Y, Ohmine K, Ono T, Matsumura I, Matsuda A, Aoki M, Ito K, Shibayama H. Nilotinib vs. imatinib in Japanese patients with newly diagnosed chronic myeloid leukemia in chronic phase: long-term follow-up of the Japanese subgroup of the randomized ENESTnd trial. Int J Hematol. 2017 Oct 26. PMID:29076005
- Rizq O, Mimura N, Oshima M, Saraya A, Koide S, Kato Y, Aoyama K, Nakajima-Takagi Y, Wang C, Chiba T, Ma A, Jin J, Iseki T, Nakaseko C, Iwama A. Dual Inhibition of EZH2 and EZH1 Sensitizes PRC2-Dependent Tumors to Proteasome Inhibition. Clin Cancer Res. 2017 Aug 15;23(16):4817-4830. PMID:28490465
- Takahashi N, Nakaseko C, Kobayashi Y, Miyamura K, Ono C, Koide Y, Fujii Y, Ohnishi K. Long-term treatment with bosutinib in a phase 1/2 study in Japanese chronic myeloid leukemia patients resistant/intolerant to prior tyrosine kinase inhibitor treatment. Int J Hematol. 2017 Sep;106(3):398-410., PMID:28409328
- Hideshima T, Cottini F, Nozawa Y, Seo HS, Ohguchi H, Samur MK, Cirstea D, Mimura N, Iwasawa Y, Richardson PG, Munshi NC, Chauhan D, Massefski W, Utsugi T, Dhe-Paganon S, Anderson KC. p53-related protein kinase confers poor prognosis and represents a novel therapeutic target in multiple myeloma. Blood. 2017 Mar 9;129(10):1308-1319. doi: 10.1182/blood-2016-09-738500. Epub 2017 Jan 12. PMID: 28082445
- Yokoyama M, Chiba T, Zen Y, Oshima M, Kusakabe Y, Noguchi Y, Yuki K, Koide S, Tara S, Saraya A, Aoyama K, Mimura N, Miyagi S, Inoue M, Wakamatsu T, Saito T, Ogasawara S, Suzuki E, Ooka Y, Tawada A, Otsuka M, Miyazaki M, Yokosuka O, Iwama A. Histone lysine methyltransferase G9a is a novel epigenetic target for the treatment of hepatocellular carcinoma. Oncotarget. 2017 Mar 28;8(13):21315-21326. doi: 10.18632/oncotarget.15528. PMID: 28423509
- Hideshima T, Mazitschek R, Qi J, Mimura N, Tseng JC, Kung AL, Bradner JE, Anderson KC. HDAC6 inhibitor WT161 downregulates growth factor receptors in breast cancer. Oncotarget. 2017 Jul 5;8(46):80109-80123. doi: 10.18632/oncotarget.19019. eCollection 2017 Oct 6. PMID: 29113288
- Isshiki Y, Tanaka H, Suzuki Y, Yoshida Y. Cyclosporine is a potential curative treatment option for advanced thymoma. Exp Hematol Oncol. 2017 May 3;6:13. doi: 10.1186/s40164-017-0073-6. eCollection 2017.
和文論文
- 大和田千桂子,中世古知昭. III-23 造血系・リンパ系疾患 原発性マクログロブリン血症.血液疾患 最新の治療2017-2019 編集:小澤敬也,中尾眞二,松村到,p213-216, 南江堂,東京,2017(単行本)
- 三村尚也 骨髄腫治療を理解するためのMyeloma Biology 2.骨髄腫の進行をもたらす骨髄腫細胞の分子病態 2) エピジェノム (1)メチル化、脱メチル化 多発性骨髄腫Updating 第10巻, 医薬ジャーナル社, 2017 page 48-57 (単行本)
- 三村尚也,中世古知昭 第2章 各種治療薬の使い方・考え方 7. パノビノスタット 多発性骨髄腫 新規治療薬の使い方・考え方,編集:石田禎夫, 先端医学社, 2017 page 124-133 (単行本)
- 三村尚也ほか(日本語版翻訳) IMF Concise Review of the Disease and Treatment Options 2015 Edition, International Myeloma Foundation. 日本語版 2017 in press (単行本)
- 武内正博,中世古知昭.2.新しい多発性骨髄腫の治療指針に基づく骨髄腫治療戦略,1)移植適応骨髄腫の治療指針.特集 多発性骨髄腫の臨床 ~現状と展望~ 血液フロンティア 2017; 27(1):31-39
- 中世古知昭.慢性骨髄性白血病の治療の進歩.特集「白血病診療の実際-最新の診断と治療」 日本医師会雑誌 2017; 145(12): 2579-83
- 高橋直人,川口辰哉,中世古知昭,西脇嘉一.慢性骨髄性白血病薬物療法の長期安全性 ―ボスチニブのテータから考える― LEUKEMIA INSIGHT 2017; 5: 2-5
- 高石浩司,堺田惠美子,中世古知昭.POEMS症候群の診断と治療.血液内科 74巻:第2号:232
- 前田隆宏, 大岡美彦, 横山昌幸, 若松徹, 井上将法, 齊藤朋子, 日下部裕子, 小笠原定久, 鈴木英一郎, 太和田暁之, 三村尚也, 堺田恵美子, 中世古知昭, 岸本充, 千葉哲博. 急性前骨髄球性白血病を併発した肝細胞癌の1例.肝臓 2017; 58(3): 176-82
- 清水直美,吉田正,松澤康雄,渡邉康弘,蛭田啓之,中世古知昭,龍野一郎.der(1;7)(q10;p10)を含む複雑染色体核型を呈した骨髄異形成症候群併存下での肺神経内分泌大細胞癌治療の経験.臨床病理 2017 in press
- 酒井紫緒,三村尚也,立花美智子,日野もえ子,竹田勇輔,武内正博,大和田千桂子,堺田惠美子,中世古知昭,井関徹.輸血・細胞療法部における同種造血幹細胞移植ドナー外来の有効性と意義.日本輸血・細胞治療学会誌 2017 in press
- 中世古知昭.慢性骨髄性白血病の病態解明と分子標的治療.「特集:白血病・病態解明と分子標的治療」 Medical Science Digest 2017; 43(8): 24-27
- 中世古知昭,大和田千桂子,堺田惠美子.骨髄腫類縁疾患の診断と治療.ALアミロイドーシス,POEMS症候群の診断と治療.「特集:慢性疾患となった骨髄腫 どのように診断するか?どのように付き合っていくか?」 内科 2017; 120(4): 949-954
- 中世古知昭.慢性骨髄性白血病の標準治療とポナチニブ.「特集:血液腫瘍の最近のトピック」 腫瘍内科 2017; 20(5): 381-388
2016
- Kanda Y, Kobayashi T, Mori T, Tanaka M, Nakaseko C, Yokota A, Watanabe R, Kako S, Kakihana K, Kato J, Tanihara A, Doki N, Ashizawa M, Kimura SI, Kikuchi M, Kanamori H, Okamoto S. A randomized controlled trial of cyclosporine and tacrolimus with strict control of blood concentrations after unrelated bone marrow transplantation. Bone Marrow Transplant. 2016; 51(1):103-9. PMID: 26437063
- Muto T, Ohwada C, Yamazaki A, Sugita S, Tsukamoto S, Sakai S, Takeda Y, Mimura N, Takeuchi M, Sakaida E, Iseki T, Shimizu N, Morio T, Nakaseko C. Long-term complete remission by infusion of ex vivo-expanded donor-derived CD4+ lymphocytes for an early relapse of Hodgkin lymphoma after cord blood transplantation. Leuk Lymphoma 2016; 57(1): 230-2. PMID: 25962436.
- Muto T, Takeda Y, Tsukamoto S, Sakai S, Mimura N, Ohwada C, Takeuchi M, Sakaida E, Ota S, Iseki T, Shimizu N, Morio T, Nakaseko C. Successful treatment of cytomegalovirus enteritis after unrelated allogeneic stem cell transplantation by the infusion of ex vivo-expanded CD4+ lymphocytes derived from the recipient’s peripheral blood donor cells. Transpalnt Infect Dis 2016;18(1):93-7. PMID: 26613364
- Muto T, Ohwada C, Sawai S, Beppu M, Tsukamoto S, Takeda Y, Mimura N, Takeuchi M, Sakaida E, Sogawa K, Misawa S, Shimizu N, Iseki T, Nomura F, Kuwabara S, Nakaseko C. Acutely deteriorated extravascular volume overload during peripheral blood stem cell mobilization in POEMS syndrome: A case series with cytokine analysis. Transfus Apher Sci 2016; 54(2): 276-81. PMID: 26586169
- Oshima M, Hasegawa N, Mochizuki-Kashio M, Muto T, Miyagi S, Koide S, Yabata S, Wendt GR, Saraya A, Wang C, Shimoda K, Suzuki Y, Iwama A. Ezh2 regulates the Lin28/let-7 pathway to restrict activation of fetal gene signature in adult hematopoietic stem cells. Exp Hematol. 2016; 44(4): 282-296. PMID: 26773568
- Yakushijin K, Atsuta Y, Doki N, Yokota A, Kanamori H, Miyamoto T, Ohwada C, Miyamura K, Nawa Y, Kurokawa M, Mizuno I, Mori T, Onizuka M, Taguchi J, Ichinohe T, Yabe H, Morishima Y, Kato K, Suzuki R, Fukuda T. Sinusoidal obstruction syndrome after allogeneic hematopoietic stem cell transplantation: incidence, risk factors, and outcomes. Bone Marrow Transplant. 2016; 51(3): 403-9. PMID: 26595082
- Isshiki Y, Ono K, Shono K, Onoda M, Yokota A. Autoimmune Thyroid Dysfunction after Allogeneic Hematopoietic Stem Cell Transplantation. Leuk Lymphoma. 2016; 57(5):1227-9. PMID: 26308103
- Sakaida E, Iwasawa S, Kurimoto R, Ebata T, Imai C, Oku T, Sekine I, Tada Y, Tatsumi K, Takiguchi Y. Safety of a short hydration method for cisplatin administration in comparison with a conventional method-a retrospective study. Jpn J Clin Oncol. 2016: 46(4):370-377 PMID: 26755829
- Ohguchi H, Hideshima T, Bhasin MK, Gorgun GT, Santo L, Cea M, Samur MK, Mimura N, Suzuki R, Tai YT, Carrasco RD, Raje N, Richardson PG, Munshi NC, Harigae H, Sanda T, Sakai J, Anderson KC. The KDM3A-KLF2-IRF4 axis maintains myeloma cell survival. Nat Commun. 2016 Jan 5;7:10258. PMID: 26728187
- Kato M, Yamashita T, Suzuki R, Matsumoto K, Nishimori H, Takahashi S, Iwato K, Nakaseko C, Kondo T, Imada K, Kimura F, Ichinohe I, Hashii Y, Kato K, Atsuta A, Taniguchi S, Fukuda T. Donor cell-derived hematologic malignancy: a survey by the Japan Society for Hematopoietic Cell Transplantation. Leukemia 2016;30(8):1742-5. PMID: 26867671
- Kozuki T, Nogami N, Kitajima H, Iwasawa S, Sakaida E, Takiguchi Y, Ikeda S, Yoshida M, Kato T, Miyamoto S, Sakamaki K, Shinkai T, Watanabe K. Feasibility study of first-line chemotherapy using Pemetrexed and Bevacizumab for advanced or recurrent non-small cell lung cancer in elderly patients: TORG1015. BMC Cancer. 2016; 16:306. PMID: 27177035
- Sarah Jarvis, Gunnar Birgegård, Tamara Lado Cives, Sélim Aractingi, Chiaki Nakaseko, Claire Harrison, Melania Moreno Vega, Jean‑Jacques Kiladjian, Salah Alimam, Manuel Martinez‑Sellés Advancing our clinical perspective in haematology: what is your approach? Summary of presentations from the 11th New Horizons in Haematology conference which took place on 11th March 2016 and was webcast live to moderated audiences in Hong Kong, Italy, Japan, Russia, South Africa, and Spain, and to individuals throughout the world. Eur Med J Haematol Supplement 2016 June, 1-9
- Shimizu R, Muto T, Aoyama K, Choi K, Takeuchi M, Koide S, Hasegawa N, Isshiki Y, Togasaki E, Kawajiri C, Nagao Y, Tsukamoto S, Sakai S, Takeda Y, Mimura N, Ohwada C, Sakaida E, Iseki T, Starczynowski DT, Iwama A, Yokote K, Nakaseko C. Possible role of intragenic DNA hypermethylation in gene silencing of the tumor suppressor gene NR4A3 in acute myeloid leukemia. Leuk Res 2016; 50: 85-94, PMID: 27697661
- Sugita Y, Ohwada C, Kawaguchi T, Muto T, Tsukamoto S, Takeda Y, Mimura N, Takeuchi M, Sakaida E, Shimizu N, Tanaka H, Abe D, Fukazawa F, Sugawara T, Aotsuka N, Nishiwaki K, Shono K, Ebinuma H, Fujimura K, Bujo H, Yokote K, Nakaseko C. Prognostic impact of serum soluble LR11 in newly diagnosed diffuse large B-Cell lymphoma: a multicenter prospective analysis. Clin Chim Acta 2016; 463: 47-52, PMID: 27725222
- Hideshima T, Qi J, Paranal RM, Tang W, Greenberg E, West N, Colling ME, Estiu G, Mazitschek R, Perry JA, Ohguchi H, Cottini F, Mimura N, Görgün G, Tai YT, Richardson PG, Carrasco RD, Wiest O, Schreiber SL, Anderson KC, Bradner JE. Discovery of selective small-molecule HDAC6 inhibitor for overcoming proteasome inhibitor resistance in multiple myeloma. Proc Natl Acad Sci U S A. 2016; 113(46): 13162-7., PMID: 27799547
- Asano T, Matsuoka KI, Iyama S, Ohashi K, Inamoto Y, Ohwada C, Murata M, Satake A, Yoshida C, Nakase K, Mori Y, Tanimoto M. Phase I/IIa Study of Low Dose Subcutaneous Interleukin-2 (IL-2) for Treatment of Refractory Chronic Graft Versus Host Disease. Acta Med Okayama. 2016;70(5):429-33., PMID: 27777442
和文論文
- 大和田千桂子,中世古知昭. 日本臨牀増刊号 多発性骨髄腫学―最新の診療と基礎研究― 第VIII章. 特殊病型と類縁疾患の診断と治療 6. POEMS症候群. p535-539, 日本臨牀社,大阪,2016(単行本) ISSN 0047-1852
- 長谷川渚,堺田恵美子,中世古知昭.日本臨牀2016年12月増刊号 白血病学(下)―最新の基礎,臨床研究―.第Ⅷ章 白血病の治療:各論(化学療法と分子標的療法),12. 移行期・急性転化期の慢性骨髄性白血病,p167-71,編集:谷脇雅史,2016(単行本)
- 武内正博,中世古知昭.診断と治療のABC 113 慢性骨髄性白血病・骨髄増殖性腫瘍 第3章 診断,3. その他の骨髄増殖性腫瘍の診断, 企画:木村文彦,最新医学社,大阪,p85-91, 2016(単行本)
- 大和田千桂子. 血液科研修ノート 第1章 血液科研修でのアドバイス A. 血液科医になる人へ 3. ワークライフバランスを考える~血液内科を生涯のプロフェッショナルとするために 監修:永井良三,編集:神田善伸,p356-9,診断と治療社,東京,2016(単行本)
- 中世古知昭. 血液科研修ノート 第5章 血液疾患の診療, C. 白血球系疾患:脾腫陽性疾患,3. 血球貪食症候群 監修:永井良三,編集:神田善伸,p,診断と治療社,東京,2016(単行本)
- 中世古知昭. II.臨床編 b 移植合併症 9.非感染性呼吸器合併症 みんなに役立つ造血幹細胞移植の基礎と臨床改訂 神田善伸編 医薬ジャーナル社,大阪,2016; p530-537(単行本) ISBN978-4-7532-2810-0
- 松井愼一郎, 竹田勇輔, 一色佑介, 山崎敦子,中尾三四郎,高石浩司, 永尾侑平, 長谷川渚, 東ヶ崎絵美, 清水亮, 川尻千華,酒井紫緒, 三村尚也, 武内正博, 大和田千桂子, 堺田恵美子,井関徹, 今留謙一,中世古知昭. 著明な心嚢水貯留を主症状として発症し,同種末梢血幹細胞移植が奏効した慢性活動性EBウイルス感染症. 臨床血液 2016; 57(5):624-629. PMID: 27263789
- 木村賢司,武内正博,長谷川渚, 東ヶ崎絵美, 清水亮, 川尻千華,武藤朋也,塚本祥吉, 竹田勇輔,大和田千桂子,堺田惠美子,酒井紫緒,三村尚也,太田聡,井関徹,中世古知昭.All-trans retinoic acid単独投与後に重度の口内炎と回盲部腸管穿孔を発症したHLA-B51陽性急性前骨髄球性白血病.臨床血液 2016;57(6):765-70. PMID: 27384858
- 中世古知昭. 私のこの一枚:30年以上の経過を有し,高度の形質細胞肺浸潤を伴った多中心性Castleman病の一例 血液フロンティア 2016; 26(7): 3-7
- 長谷川渚,堺田惠美子,中世古知昭.ボスチニブとCML. 特集/血液腫瘍の最近のトピックス-新たに保険承認されたありは適応拡大された造血器腫瘍に対する薬剤.腫瘍内科 2016; 17(6): 599-604
- 三村尚也, 岩間厚志. 多発性骨髄腫におけるエピジェネティック異常 日本臨牀2016年5月増刊号 多発性骨髄腫学-最新の診療と基礎研究- 2016; 74(5): 163-167.
- 高橋直人,中世古知昭,川口辰哉,西脇嘉一. 慢性骨髄性白血病の長期安全性-ボスチニブのデータから考える Leukemia Insight in press
- 堺田惠美子. 悪性腫瘍の病態と治療 SBO 105 悪性腫瘍の治療における薬物治療の位置づけ. 日本薬学会スタンダード薬学シリーズ 総監修 市川厚 第6巻 薬と疾病 Ⅲ. 薬物治療(2)および薬物治療に役だつ情報 第3版 東京化学同人 2016年12月 in press
- 中世古知昭. 多発性骨髄腫に対する造血幹細胞移植 日本内科学会雑誌 2016; 105(7):1246-1254
- 酒井紫緒. 造血幹細胞採取の実際 平成28年度HCTC認定講習テキスト 2016 p11-17,p5-9,JSHCT monograph Vol.43 一般社団法人日本造血細胞移植学会,名古屋,2016,ISSN1344-5898(単行本)
- 川尻千華,中世古知昭.POEMS症候群〜いかに考え、治療するか〜.Pharma Medica 2016; 34(1):75-79.
- 前田隆宏,千葉哲博,大岡美彦,横山昌幸,若松徹,井上将法,日下部裕子,齋藤朋子,小笠原定久,鈴木英一郎,太和田暁之,堺田恵美子,中世古知昭,井関徹,岸本充,横須賀收.再生不良性貧血による高度な汎血球減少を伴った肝細胞癌に対して治療介入を行った2例.肝臓 2016; 57(10): 557-560.